EUVIMEDEUVIMED entdecken
VergleichsstudieNetzwerk-MetaanalyseOpen Access · CC BY-NC 4.0

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Jennifer I Lim, Theodore Leng, Jakob Siedlecki, Marco Lupidi, John A Wells, Pearse A Keane, Eric Nudleman, Florie Mar, Kara Gibson, Philippe Margaron, David Tabano, Christian Bührer und 1 weitere

Ophthalmic Research · 2026

DOI: 10.1159/000552388 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Ophthalmic Research, 2026. Verfasst von Jennifer I Lim und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Science, University of Illinois at Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Recombinant Fusion Proteins, Receptors, Vascular Endothelial Growth Factor, Diabetic Retinopathy, Macular Edema. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NEI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Matching-adjusted network meta-analyses (NMAs) provide an established method to indirectly compare treatments across trials that share a common comparator. In this exploratory analysis, we conducted a matching-adjusted NMA to compare the efficacy of faricimab with aflibercept 8 mg for treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) via the common comparator of aflibercept 2 mg during the first 12 weeks of treatment when all agents are dosed equally.

Methods

Weighting was applied to match patient populations from YOSEMITE/RHINE (NCT03622580/NCT03622593) and TENAYA/LUCERNE (NCT03823287/NCT03823300) based on their baseline characteristics to published aggregated baseline characteristics for PHOTON (NCT04429503) and PULSAR (NCT04423718), respectively. The matched populations were used to recalculate outcomes from faricimab trials and an NMA anchored to aflibercept 2 mg was conducted. The analysis focused on change in best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study letters and central subfield thickness (CST) in µm during the first 12 weeks of treatment when dosing was every 4 weeks for all three agents. Results are expressed as mean difference in change in BCVA or CST for each aflibercept dose.

Results

For nAMD, BCVA change was similar between faricimab and aflibercept 2 mg and 8 mg, whereas CST reduction was greater for faricimab versus aflibercept 8 mg (−17.0 µm; 95% credible interval [CrI], −25.0, −8.4) and 2 mg (−19.0 µm; 95% CrI, −24.0, −13.0). For DME, BCVA change from baseline at 12 weeks was similar between faricimab and aflibercept 2 mg and 8 mg, while CST reduction was greater for faricimab versus aflibercept 8 mg (−19.0 µm; 95% CrI, −35.0, −3.2) and 2 mg (−19.0 µm; 95% CrI, −27.0, −12.0).

Conclusion

This matching-adjusted NMA indicated that dual angiopoietin-2/vascular endothelial growth factor (VEGF)-A inhibition with faricimab was associated with greater retinal drying during the matched-dosing phase in patients with nAMD and DME. Early dual pathway inhibition may therefore improve outcomes beyond anti-VEGF monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorDiabetic RetinopathyMacular EdemaVisual AcuityWet Macular DegenerationHumansAngiogenesis InhibitorsIntravitreal InjectionsTreatment OutcomeFemaleMaleDose-Response Relationship, DrugTomography, Optical CoherenceAgedAntibodies, Bispecific

Stichwörter der Autor:innen

AfliberceptDiabetic macular edemaFaricimabMatching-adjusted network meta-analysisNeovascular age-related macular degeneration

Substanzen

Recombinant Fusion ProteinsReceptors, Vascular Endothelial Growth FactorafliberceptAngiogenesis InhibitorsfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Ophthalmology and Visual Science, University of Illinois at Chicago, Chicago, Illinois, USA.
  • Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, USA.
  • Department of Ophthalmology, University Hospital, LMU Munich, Munich, Germany.
  • Eye Clinic, Polytechnic University of Marche, AOU delle Marche, Ancona, Italy.
  • Palmetto Retina Center, Columbia, South Carolina, USA.
  • NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust, London, UK.

Förderung

  • NEI NIH HHS

Zitieren

APA

Lim, J. I., Leng, T., Siedlecki, J., Lupidi, M., Wells, J. A., Keane, P. A., Nudleman, E., Mar, F., Gibson, K., Margaron, P., Tabano, D., Bührer, C., & Holekamp, N. (2026). A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic Research. https://doi.org/10.1159/000552388

Vancouver

Lim JI, Leng T, Siedlecki J, Lupidi M, Wells JA, Keane PA, et al. A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. Ophthalmic Research. 2026. doi:10.1159/000552388

BibTeX
@article{Lim2026,
  author = {Lim, Jennifer I and Leng, Theodore and Siedlecki, Jakob and Lupidi, Marco and Wells, John A and Keane, Pearse A and Nudleman, Eric and Mar, Florie and Gibson, Kara and Margaron, Philippe and Tabano, David and Bührer, Christian and Holekamp, Nancy},
  title = {A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema},
  journal = {Ophthalmic Research},
  year = {2026},
  doi = {10.1159/000552388}
}
Kostenlos starten →